Fixed-duration vs continuous therapy in CLL

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, compares defined duration versus continuous therapy in chronic lymphocytic leukemia (CLL), commenting on the possibility of finding biomarkers to define the length and intensity of treatment for each patient, and highlighting promising results from the HOVON-141/VISION trial (NCT03226301). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.